Ultragenyx Pharmaceutical (RARE) Gets a Buy from J.P. Morgan
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on March 6 and set a price target ...
Ultragenyx assumed with an Overweight at Morgan Stanley
Morgan Stanley assumed coverage of Ultragenyx (RARE) with an Overweight rating and $64 price target The firm sees continued strong Crysvita ...
Nasdaq19d
Ultragenyx to Participate at Investor Conferences in March
Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings. Wednesday, March 12, 2025, Eric Crombez will participate in a fireside ...